Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    8443385 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Daclizumab to Treat Chronic Immune Thrombocytopenia
Condition: Thrombocytopenia
Intervention: Drug: Daclizumab

Indicates status has not been verified in more than two years